| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.006 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.48 | 0.007 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.007 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |